… of trace minerals in the pathogenesis of postmenopausal osteoporosis and a new effect of calcitonin -
A G?r, L ?olpan, K Nas, R ?evik, J Sara?, F … - Journal of Bone and Mineral Metabolism, 2002 - Springer
... Serum Zn 1.22 0.31 0.609 0.37* 0.646 0.34* , ** 0.765 ... Lippincott-Raven, New York,
pp 41?46 ... al.: Trace minerals in postmenopausal osteoporosis and calcitonin ...
A new tracer method for the calculation of rates of bone formation and breakdown in osteoporosis and … -
J Reeve, R Hesp, R Wootton - Calcified Tissue International, 1977 - Springer
... These 18 new sets of data were then analysed to ... Calculation of Bone Formation and
Breakdown in Osteoporosis ... 60 80 (a) laaBa 0.0 a 0.45 0.28 --0.45 --0.37 ...
What's new in preventing and treating osteoporosis -
WC Andrews - Postgrad Med, 1998 - postgradmed.com
... protective effect, with a relative risk of 0.37 (CI, 0.13 ... It is reasonable to anticipate
five to ten new therapies for osteoporosis becoming available ...
-
IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis -
A Cranney, G Guyatt, L Griffith, G Wells, P … - Endocrine Reviews, 2002 - Endocrine Soc
... vitamin D is 0.0012 x 0.37 = 0.000444 (0.04 ... predict hip fractures and new vertebral
deformities ... of etidronate for the treatment of postmenopausal osteoporosis. ...
Assessment of a New Quantitative Ultrasound Calcaneus Measurement: Precision and Discrimination of … -
YQ He, B Fan, D Hans, J Li, CY Wu, CF Njeh, S Zhao … - Osteoporosis International, 2000 - Springer
... SOS ? Sahara 0.001+0.0004 (gs/cm 2 m) 0.37 <0.01 ... of ultrsound in the assessment of
osteoporosis: a review ... Cummings S, Genant H. Searching for new and improved ...
Application of a New Serum Assay for Type I Collagen Cross-Linked N-Telopeptides: Assessment of … -
BJ Gertz - Calcified Tissue International, 1998 - Springer
... of ~33% (10.08 ? 0.71 versus 6.75 ? 0.37 nmol BCE ... In: Riggs BL, Melton LJ III,
(eds) Osteoporosis. Raven Press, New York, pp 297?316 3. Seibel MJ, Robins ...
… influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. -
NA Morrison, PM George, T Vaughan, MW Tilyard, CM … - Pharmacogenetics and Genomics, 2005 - jpharmacogenetics.com
... trial when treated with calcitriol (OR=0.37, 95% CI ... Because the new fracture rate
is low in the ... originally suggested to protect against osteoporosis [17]: the ...
2MD, a new anabolic agent for osteoporosis treatment -
LA Plum, LA Fitzpatrick, X Ma, NC Binkley, JB … - Osteoporosis International, 2006 - Springer
... ORIGINAL ARTICLE 2MD, a new anabolic agent for osteoporosis treatment LA Plum .
LA Fitzpatrick . X. Ma . NC Binkley . JB Zella . M. Clagett-Dame . HF DeLuca ...
A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis -
M Kleerekoper, EL Peterson, DA Nelson, E Phillips, … - Osteoporosis International, 1991 - Springer
... Fluoride 42 111.13 5 45 0.48 (0.10-2.39) 0.37 ... P. Long-term fluoride therapy of
postmenopausal osteoporosis. ... New York: Wiley, 1977: chapter 6. 7. Laird NM, Ware ...
IV. Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis -
A Cranney, P Tugwell, N Zytaruk, V Robinson, B … - Endocrine Reviews, 2002 - Endocrine Soc
... Lufkin trial 0.52 (95% CI 0.12?2.18, P = 0.37) (6, 14 ... Med Assoc J Home page ER Yendt
Osteoporosis guidelines Can ... Alert me when: new articles cite this article. ...
Source: Google Scholar |